MONITOR PsA (Cohort)
Research type
Research Study
Full title
A multicentre observational psoriatic arthritis cohort study addressing real-life outcomes of a treat to target approach in routine clinical practice.
IRAS ID
230600
Contact name
Laura Coates
Contact email
Sponsor organisation
University of Oxford
Eudract number
2017-002230-24
Duration of Study in the UK
5 years, 0 months, 0 days
Research summary
Psoriatic Arthritis (PsA) is an inflammatory arthritis estimated to occur in 15% of people with psoriasis, affecting around 150,000 people in the UK. Two-thirds of people with PsA suffer progressive joint damage with associated disability. People with PsA have similar functional and quality of life impairment to rheumatoid arthritis. PsA is associated with a reduced life expectancy related to the risk of comorbidities, particularly the metabolic syndrome. Direct costs to healthcare are estimated at £2,400 per patient annually with indirect costs (time lost from work and activities) per patient of over £8,000.
The 2015 European League Against Rheumatism (EULAR) Treatment recommendations for PsA incorporating as its first recommendation that “treatment should be aimed at reaching the target of remission or, alternatively, minimal/low disease activity, by regular monitoring and appropriate adjustment of therapy”. Despite the evidence and the EULAR recommendations supporting ‘treat to target’ in PsA, it has not been widely implemented due to concerns about feasibility and cost-effectiveness. This cohort will establish a pragmatic feasible ‘treat to target’ approach in a real-life clinic population which we believe can provide similar clinical and health-related quality of life outcomes.
The primary outcome will be the proportion of patients achieving a good response measured by the PsA Disease Activity Score (PASDAS) at 48 weeks. Additional domains including participation, fatigue and emotional wellbeing will be assessed for the first time. Finally the costs of this pragmatic intervention will be established using health economic analysis.REC name
South Central - Oxford C Research Ethics Committee
REC reference
17/SC/0556
Date of REC Opinion
1 Nov 2017
REC opinion
Favourable Opinion